A synthetic adjuvant to enhance and expand immune responses to influenza vaccines - sprookjes - yvandenbroek - TriplyDB

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines

http://www.wikidata.org/entity/Q28748680

about

sameAs

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant Development of the Brazilian Anti Schistosomiasis Vaccine Based on the Recombinant Fatty Acid Binding Protein Sm14 Plus GLA-SE Adjuvant The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations Novel structurally designed vaccine for S. aureus α-hemolysin: protection against bacteremia and pneumonia Clinical vaccine development for H5N1 influenza.Salmonella Typhi Porins OmpC and OmpF Are Potent Adjuvants for T-Dependent and T-Independent Antigens.Adjuvant solution for pandemic influenza vaccine production Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140.A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens Bacterial lysates improve the protective antibody response against respiratory viruses through Toll-like receptor 4.Vaccinating captive chimpanzees to save wild chimpanzees.The narrowing of the CD8 T cell repertoire in old age A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate.Trial Watch: Peptide-based anticancer vaccines.Clinical adjuvant combinations stimulate potent B-cell responses in vitro by activating dermal dendritic cells Structurally designed attenuated subunit vaccines for S. aureus LukS-PV and LukF-PV confer protection in a mouse bacteremia model.Vaccine self-assembling immune matrix is a new delivery platform that enhances immune responses to recombinant HBsAg in mice Transcriptional profiling of TLR-4/7/8-stimulated guinea pig splenocytes and whole blood by bDNA assay.Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors.GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults.Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials The importance of adjuvant formulation in the development of a tuberculosis vaccine.Schistosome Vaccine Adjuvants in Preclinical and Clinical Research.Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants.A history of hookworm vaccine development.The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction.A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses Vaccination Produces CD4 T Cells with a Novel CD154-CD40-Dependent Cytolytic Mechanism Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines.A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I·C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mi Optimization of a methamphetamine conjugate vaccine for antibody production in mice Optimizing Immunization Strategies for the Induction of Antigen-Specific CD4 and CD8 T Cell Responses for Protection against Intracellular Parasites.MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant Development of a schistosomiasis vaccine.Production of Cytomegalovirus Dense Bodies by Scalable Bioprocess Methods Maintains Immunogenicity and Improves Neutralizing Antibody Titers.A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93.

P2860

Q21091066-C890FC38-1C68-4187-BC98-D08C39A02719 Q26991992-D307BEDF-CC8B-4206-A65C-38A8942C021A Q27025076-5F9F47E1-7E8F-44E7-8D87-2D2ED2741222 Q27312129-9513CB86-550C-48A6-AFD5-B5B50D377A21 Q27321020-8A3DC25A-D87C-476A-804D-7223A5FFEF57 Q28728777-ABB715D5-0CDB-47DC-8731-83D53452C32F Q30222083-DDFB5EB9-F68A-40A7-9AE1-114597DA6CD3 Q30400261-9C4DC744-5665-456C-B650-F6A7BAE8D3FF Q30422038-16FBF65A-200C-43C2-97C4-9885F8908C62 Q31076192-C84F968B-EE2F-4F6C-8899-39A4DA06A05C Q33720317-8730A4FA-EBE2-4CC5-A566-3FA9192C1C6F Q33723524-56B6AED4-2958-43BB-8613-4B0BBF05E2AF Q33790197-A549CCCA-66B3-4090-B29A-3512FCE028FB Q34190605-86EA6576-16E2-4A57-BFE1-A67475B5F0C5 Q34232909-B4095768-3DE0-481C-9492-F4BDBD701C3D Q34483345-12D2C71D-C183-482F-977F-B2BDCADAE1A4 Q34735203-FAB4E995-C66A-4D17-A67F-D740F87408B0 Q34769869-BBC5D6DF-27E7-4733-8942-BEB4DEF81B48 Q35122785-E3B28023-2FB8-4420-94CF-8557DBDFE0FF Q35377667-05F28263-9D82-42D7-9204-0E7AF88AB482 Q35412152-0D33B286-B5D9-410C-95D2-413D89AB8764 Q35669044-FCD5C164-7BA2-419A-AAB2-6F5FBB9CDD2B Q35761061-84EB6D43-DDD4-45C2-A90A-0E11122D2482 Q35783475-B6AFA643-4C35-473E-9D11-57A502FFD1E9 Q35826651-3AC2847B-6A06-4C45-A4FE-38ED30BE30E0 Q35836140-BCFE990C-AD80-45C0-ABF1-22BE905D1EAA Q35881296-6D8F07D4-BA6A-44F8-B3C1-1136A4825D15 Q35885464-13C4B80C-673D-46ED-B56E-8872968B90AD Q35990046-51615B68-1DF5-46A1-BD62-69B8C18194D5 Q36075279-A5E2C070-A132-4C8C-8840-FFDD2CCE97FB Q36362230-D9BB0D88-C9CF-44A3-AD0D-60F65417B1AC Q36452968-FB8C314B-8305-4A87-B9B2-868361D8C390 Q36500269-12B720AB-B5F2-4F80-A3E8-4BD025E89536 Q36646698-7E58DC5E-011B-4811-936F-EF67EEF791BF Q36854009-7F19AA97-F6E2-4347-BAD6-7C08875566A7 Q37239554-A9107C22-CF53-4A3F-A66D-C390C8781191 Q37243896-452DC463-D394-4B75-925C-5D978A33A885 Q37350747-CCE12453-F2AD-4913-AE59-C3A16C1D1A00 Q37409233-415A7066-2254-464E-91EB-D4151EB3ED90 Q37431320-26A0D32D-B44C-49DB-BDD2-DC57F8E71B06

P2860

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines

http://www.wikidata.org/entity/Q28748680

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines

@ast

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines

@en

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines

@nl

type

label

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines

@ast

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines

@en

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines

@nl

prefLabel

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines

@ast

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines

@en

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines

@nl

P1433

Q28748680-85060FD9-8688-4060-AE76-D544D3FEFD9E

P1476

Q28748680-3927F654-0CC7-42E8-BFA9-9FB0868D4D82

P2093

Q28748680-3667A126-9B0E-4161-B2BE-7547DECBDC69

Q28748680-5BD42399-3FDE-4CDF-95F3-027A94049211

Q28748680-5E2ABEA5-BE53-42FA-AA23-33285D124A11

Q28748680-689AA176-C329-4DA4-B8E4-45C2CC6343FF

Q28748680-74C223F7-6146-44CB-90DC-2ECED48325D5

Q28748680-7F070872-A691-4B67-9D1F-5F3680188919

Q28748680-A8E82335-0A00-4ABD-A60E-E73196F54AD1

Q28748680-AFF6456F-41E3-4449-B3FF-00133D4B6D3A

Q28748680-D1E36C14-5797-40B6-B31E-D5AC34B9071F

Q28748680-E4D9FC2D-9AE4-4371-83BD-82B255D91468

P2860

Q28748680-0F67DA66-7FA4-4288-B054-5386BDF38C06

Q28748680-12B0B6D2-76DF-4450-A2CA-EA81A8C06F4E

Q28748680-26586631-9337-4D85-B394-70634E701DF7

Q28748680-409D1DED-2A57-4183-AA5B-F3DC96B7750E

Q28748680-4CACB4EE-E15C-449A-85D8-E95B4063A3CE

Q28748680-54D498B9-E53A-486E-9A75-6D8703052FD8

Q28748680-5F12AE98-C2D7-4515-8781-4E8203EAC2C7

Q28748680-6498AFBF-2DA5-4EB0-B82A-DFF6EF832717

Q28748680-66847625-30DD-4E26-A9EB-AF49C88F5D36

Q28748680-66D8B169-C307-4DA1-8D96-832B81A47E9A

P304

Q28748680-37170423-13A8-4BF6-83D4-1611A29B46E3

P31

Q28748680-84D79600-9BCB-4EB2-9306-A11324BACD9D

P3181

Q28748680-31E0D73B-82B2-4B30-B9B7-D9D15288BAF1

P356

Q28748680-259153B6-0E46-4A5D-AAAF-24126EFB6750

P407

Q28748680-AABEFC91-84C9-47E8-802B-3FF96829EE2F

P433

Q28748680-A7546A6D-9C23-4D66-B9D1-805B33301A4B

P478

Q28748680-2968BFA8-4B3D-4F1F-8941-7FC766717816

P50

Q28748680-72E4BD0F-D7A0-405B-AAD4-AB23CA8995DB

Q28748680-953151B7-F142-46CF-8509-F0351A674EF6

Q28748680-972B3213-CD4D-4922-A43B-0375F8E25FE2

Q28748680-E38C94E6-8FD1-4992-9A51-3C8BE5649238

P577

Q28748680-C5BA75B4-F180-42E7-A334-83BD2469D03E

P5875

Q28748680-AA748641-D112-460E-B80E-D96F96F2A391

P698

Q28748680-4296D36F-89B5-4843-A6F6-BC98261FDE43

P932

Q28748680-A49BB673-5A12-417F-9F25-A80E857E7EB4

P3181

P356

JOURNAL.PONE.0013677

P1433

P1476

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines

@en

P2093

Christopher H Clegg

http://www.w3.org/2001/XMLSchema#string

Joshua DeVos

http://www.w3.org/2001/XMLSchema#string

Kathy Hancock

http://www.w3.org/2001/XMLSchema#string

Neal Van Hoeven

http://www.w3.org/2001/XMLSchema#string

Rhea N Coler

http://www.w3.org/2001/XMLSchema#string

Steven J Reed

http://www.w3.org/2001/XMLSchema#string

Susan L Baldwin

http://www.w3.org/2001/XMLSchema#string

Sylvie Bertholet

http://www.w3.org/2001/XMLSchema#string

Thomas S Vedvick

http://www.w3.org/2001/XMLSchema#string

Vanitha S Raman

http://www.w3.org/2001/XMLSchema#string

P2860

Influenza vaccine: the challenge of antigenic drift.

Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

The public health impact of avian influenza viruses.

Emulsion-based adjuvants for influenza vaccines.

The effect of age on the B-cell repertoire.

Compromised influenza virus-specific CD8(+)-T-cell memory in CD4(+)-T-cell-deficient mice.

Haemagglutination-inhibiting antibody to influenza virus.

CD4 T cell responses to influenza infection.

Bone marrow is a major site of long-term antibody production after acute viral infection

In vivo blockade of gamma interferon affects the influenza virus-induced humoral and the local cellular immune response in lung tissue.

P304

e13677

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4280917

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PONE.0013677

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Narek Shaverdian

Jacqueline M. Katz

P577

2010-10-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47718804

http://www.w3.org/2001/XMLSchema#string

P698

21060869

http://www.w3.org/2001/XMLSchema#string

P932

2965144

http://www.w3.org/2001/XMLSchema#string